February 25, 2002
Positive results were reported from a phase I trial of PT-141, Palatin Technologies' medication for male and female sexual dysfunction. The double-blind, placebo-controlled trial evaluated escalating doses of PT-141 in 88 healthy male subjects. Results indicated that both intranasally and subcutaneously administered PT-141 were well tolerated over a range of doses. Neither dosage form produced serious side effects, and a maximum tolerated dose could only be reached with subcutaneous dosing. Additionally, subjects who received PT-141 at effective dose levels had erections sufficient for sexual intercourse (as defined by RigiScan Plus System score) for a duration of more than one hour relative to placebo.